Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort

Study limitation reported by the research below: “Study design is observational with no randomized comparator; causal inference regarding treatment effects is limited.”